A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs).

Melissa Lynne Johnson,Helena Alexandra Yu,Eric M. Hart,Rebekah Worden,Alfred W. Rademaker,Rajesh Gupta,Claire Miller,Jyoti D. Patel,Mark G. Kris,Vincent A. Miller,Gregory J. Riely

A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs).

2017

Melissa Lynne Johnson
Helena Alexandra Yu
Eric M. Hart
Rebekah Worden
Alfred W. Rademaker
Rajesh Gupta
Claire Miller
Jyoti D. Patel
Mark G. Kris
Vincent A. Miller
Gregory J. Riely

3083 Background: AUY922 is a highly potent, non-geldanamycin analog, HSP90 inhibitor that degrades mutated EGFR and MET. Preclinical studies demonstrate that HSP90 inhibitors have anti-tumor activi...

Keywords:

Hsp90
Erlotinib
Medicine
Mutant
Hsp90 Inhibitor AUY922
Pathology
Hsp90 inhibitor
EGFR Tyrosine Kinase Inhibitors
Cancer research
Lung cancer
dose escalation
acquired resistance

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations